Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Autor: John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew S Paulson, Joleen M Hubbard, Andrew L Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon M Kasi, Heinz-Josef Lenz, Kristen K Ciombor, Elena Elez, David L Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios S Bekaii-Saab, Marc Peeters, Marc Van den Evnde, Christophe Borg, Matthieu Sarabi, Francois Ghiringhelli, Benoist Chibaudel, Maria G. Zampino, Susana R. Keranen, Ramon Salazar, Pilar Alfonso, John H. Strickler, Andrew S. Paulson, Joleen M. Hubbard, Andrew L. Coveler, Pashtoon M. Kasi, Kristen K. Ciombor, David L. Bajor, Tanios S. Bekaii-Saab, Olumide Gbolahan, Patrick Boland, Daniel Berg, Timothy Goggins, Anwar Saeed, Howard Burris, Johanna Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel Catenacci, Jun Gong, Ignacio Garrido-Laguna, Gene Finley, Benjamin Weinberg, Anthony Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher Chen, James Ford, Madappa Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer Shao

Publikováno v: The Lancet Oncology. 24:496-508

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7adfd2ad44d4d2c2a9c7ef887cf177ac
https://doi.org/10.1016/s1470-2045(23)00150-x